
|Articles|August 28, 2014
- Head and Neck Cancers (Issue 1)
- Volume 1
- Issue 1
Unmet Needs in the Treatment of Thyroid Cancer
Author(s)Lori J. Wirth, MD
Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses areas of unmet need in the field of thyroid cancer.
Advertisement
Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses areas of unmet need in the field of thyroid cancer.
Read about molecular markers and the diagnosis of thyroid cancer > >
Articles in this issue
over 11 years ago
Immunotherapy in Head and Neck Cancersover 11 years ago
Molecular Markers Emerge in the Diagnosis of Thyroid Cancerover 11 years ago
Results of the SELECT Trial in Thyroid Cancerover 11 years ago
Update on Targeted Therapies in Head and Neck CancersAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















